Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Status Recruiting

Clinical Trial Summary

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment, adalimumab, but only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06058520
Study type	Interventional
Source	University of Minnesota
Contact	Irmina Wallander
Phone	(612) 624-5721
Email	wall0396@umn.edu
Status	Recruiting
Phase	Early Phase 1
Start date	October 1, 2023
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02904902` - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa	Phase 3
Completed	`NCT03628924` - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 2
Not yet recruiting	`NCT05531747` - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa	N/A
Recruiting	`NCT06028230` - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Completed	`NCT03275870` - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Phase 1/Phase 2
Completed	`NCT03248531` - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	Phase 2
Withdrawn	`NCT04100083` - Spironolactone for Hidradenitis Suppurativa	Phase 4
Completed	`NCT00329823` - Etanercept in Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT05710393` - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed	`NCT04019041` - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa	Phase 2
Completed	`NCT05286567` - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.	Phase 1
Withdrawn	`NCT03929835` - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa	Phase 2
Terminated	`NCT04325607` - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa	N/A
Terminated	`NCT03238469` - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa	N/A
Completed	`NCT04449354` - HidraWear AX HS Study	N/A
Recruiting	`NCT06123429` - Mindfulness in Hidradenitis Suppurativa	N/A
Recruiting	`NCT05934825` - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa	Phase 1/Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT06046729` - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2